AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02459691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Only
Description: Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
Study NCT01806259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo looking like the Active drug
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab might be expected based on their molecular tumor profile.
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Avelumab might be expected based on their molecular tumor profile.
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Erlotinib might be expected based on their molecular tumor profile.
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib plus Cobimetinib (combination)
Description: Vemurafenib plus Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib plus Cobimetinib might be expected based on their molecular tumor profile.
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Pertuzumab (combination)
Description: Trastuzumab plus Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab plus Pertuzumab might be expected based on their molecular tumor profile.
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Trastuzumab emtansine might be expected based on their molecular tumor profile.
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vismodegib might be expected based on their molecular tumor profile.
Study NCT04341181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Niraparib might be expected based on their molecular tumor profile.
Study NCT03127228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard mechanical debridement
Description: Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
Study NCT03127228 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard mechanical debridement
Description: Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
Study NCT03127228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser-assisted debridement
Description: Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
Study NCT01160770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Description: Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
Study NCT03380039 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-BCMA T cells
Description: Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied.
Study NCT03380039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.
Study NCT03380039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.
Study NCT01728467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
Study NCT01728467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, RVX000222
Description: capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
Study NCT00087633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
Study NCT00087633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
Study NCT03026673 — intervention group
Intervention type: OTHER
Intervention: NSAID use
Description: The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
Study NCT00575744 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Sentinel Node Biopsy
Description: Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
Study NCT03575832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Complete nutrition counseling sessions
Study NCT03575832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive an exercise plan and printed materials
Study NCT03575832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03575832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03575832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone coaching calls
Study NCT04035772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wiki101 and WikiTrauma
Description: Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
Study NCT03976986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous-flow portable oxygen concentrator (cPOC)
Description: SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
Study NCT03976986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed-flow portable oxygen concentrator (pPOC)
Description: InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
Study NCT00550836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV
Study NCT00550836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00550836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00550836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00550836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT04579913 — intervention group
Intervention type: OTHER
Intervention: Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound
Description: Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
Study NCT00427804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: 0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
Study NCT03374124 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sinonasal outcome test-22
Description: Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
Study NCT06453993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exhaled VOC breath test
Description: To determine longitudinal variation in exhaled VOC concentrations during intended curative therapy for EC cancer.
Study NCT02944877 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: social media intervention
Description: social media intervention
Study NCT02944877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social media intervention
Description: social media intervention
Study NCT02154815 — intervention group
Intervention type: OTHER
Intervention: Questionnaires : Patient-Reported Outcomes
Description: Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, 24, 36, 48, 72 months
Study NCT01350427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Description: 1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
Study NCT01350427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Description: 1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
Study NCT01350427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine supplementation
Description: 1 bout of resistance exercise and supplementation of 9.6 g of alanine
Study NCT00835497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets
Description: 1 x 5 mg/500 mg, single-dose fasting
Study NCT00835497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg/500 mg METAGLIP™ Tablets
Description: 1 x 5 mg/500 mg, single-dose fasting
Study NCT03832959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnsoETM
Description: The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
Study NCT03194646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen).
Study NCT03194646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen).
Study NCT03194646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen).
Study NCT03194646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
Study NCT03194646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
Study NCT03194646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
Study NCT03194646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
Study NCT02622607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
Study NCT04092608 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GDFT
Description: The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable \< 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
Study NCT04092608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LOW CVP (restrictive group)
Description: Goal = CVP \< 7mmHg and only 2 ml/kg/h max during surgery.
Study NCT00194116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium ER
Description: Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
Study NCT00194116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: . Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
Study NCT01060007 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation
Study NCT01060007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01060007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT01060007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study NCT01060007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02892435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incisional negative pressure wound therapy
Description: positioning incisional negative pressure therapy over closed wound.
Study NCT02892435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional dressing
Description: positioning conventional dressing
Study NCT02025400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eRehab
Description: Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders.
Study NCT02025400 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formal Physical Therapy
Description: This intervention involves referral to a licensed physical therapist or supervised ATC-L.
Study NCT03894059 — intervention group
Intervention type: OTHER
Intervention: Educational Intervention
Description: Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
Study NCT00792142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00792142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT00792142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00792142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT00792142 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Performed on baseline and post transplant bone marrow specimens
Study NCT00792142 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Performed on baseline and post transplant bone marrow specimens
Study NCT00792142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
Study NCT00792142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
Study NCT03812718 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube (ETT)
Description: After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
Study NCT03812718 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Description: After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
Study NCT01349283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepavaxGene (thiomersal free)
Description: 10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
Study NCT01349283 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: 10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
Study NCT04542629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiTUXimab Injection [Rituxan]
Description: 375 MG/M2 /WEEK INFUSION
Study NCT04542629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection [Rituxan]
Description: 375 MG/M2 /WEEK INFUSION
Study NCT02909322 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Hydromorphone
Description: Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
Study NCT02909322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ropivacaine and Hydromorphone
Description: Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
Study NCT02138318 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High definition (HD) endoscopy